AB18051

Anti-Osteoprotegerin 抗体 [bony-1]

Anti-Osteoprotegerin antibody [bony-1]

Be the first to review this product! Submit a review

(1 Publication)

Rat Monoclonal Osteoprotegerin antibody. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF11B aa 1-250.

別名を表示する

OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin

1 Images

Flow Cytometry - Anti-Osteoprotegerin antibody [bony-1] (AB18051)

Flow Cyt

Unknown

Flow Cytometry - Anti-Osteoprotegerin antibody [bony-1] (AB18051)

FACS analysis of cells with ab18051.
HEK 293T cells (5 x 10⁵) were mock transfected (thin line) or transfected with an expression plasmid enabling surface expression of the TNFR homology domain of human OPG (thick line). Cells were incubated on ice for 30 min in 50μl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide)
containing 1μg/ml of ab18051. After washing in FACS buffer, R-PE-conjugated antibody to rat IgG was added. Cells were incubated on ice for 30 min, washed and then analyzed by Flow Cytometry.

Key facts

宿主種

Rat

クローン性

Monoclonal

クローン番号

bony-1

アイソタイプ

IgG2a

キャリアフリー

交差種

Human

アプリケーション

Flow Cyt

applications

免疫原

Recombinant Fragment Protein within Human TNFRSF11B aa 1-250. The exact immunogen used to generate this antibody is proprietary information.

O00300

特異性

Recognizes human OPG

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/1000", "FlowCyt-species-notes": "<p><a href='/products/primary-antibodies/rat-igg2a-kappa-monoclonal-rtk2758-isotype-control-ab18450'>ab18450</a> - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.</p>" } } }

style

left-column

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Proprietary technique

精製に関する特記事項

Purified from concentrated hybridoma tissue culture supernatant.

バッファー組成

Preservative: 0.02% Sodium azide Constituents: PBS

出荷温度

Blue Ice

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor is a glycoprotein with a mass of approximately 60 kDa. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-Β ligand (RANKL) and is encoded by the TNFRSF11B gene. OPG is mainly expressed in osteoblasts fibroblasts and endothelial cells. Its expression can be found in diverse tissues throughout the body including the liver and lungs.

Biological function summary

OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.

Pathways

OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.

OPG has a significant association with conditions such as osteoporosis and vascular calcification. In osteoporosis an imbalance in the RANKL/OPG ratio can lead to excessive bone loss due to increased osteoclast activity. In vascular calcification OPG appears to play a protective role likely linked with regulatory mechanisms involving RANKL and TRAIL. Understanding these interactions opens potential therapeutic avenues particularly in managing bone-related and cardiovascular conditions.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

See full target information TNFRSF11B

style

left-column

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 11:23649 PubMed34880328

2021

INTS8 is a therapeutic target for intrahepatic cholangiocarcinoma via the integration of bioinformatics analysis and experimental validation.

Applications

Unspecified application

Species

Unspecified reactive species

Qi Zhou,Li Ji,Xueying Shi,Dawei Deng,Fangyue Guo,Zhengpeng Wang,Wenhui Liu,Jinnan Zhang,Shilin Xia,Dong Shang

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Osteoprotegerin 抗体 [bony-1]

Anti-Osteoprotegerin antibody [bony-1]

Flow Cytometry - Anti-Osteoprotegerin antibody [bony-1] (AB18051)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

特異性

Reactivity data

出荷温度及び保存条件

製品の状態

精製方法

精製に関する特記事項

バッファー組成

出荷温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (1)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Assay Kits

Complementary Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Abcam product promise